Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent.
暂无分享,去创建一个
A. Y. Lu | W. Atkins | A Y Lu | W M Atkins | R W Wang | D J Newton | N Liu | D. Newton | Regina W. Wang | R. Wang | N. Liu | Nini Liu
[1] S D Hall,et al. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. , 1994, Biochemical pharmacology.
[2] J. Halpert,et al. Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[3] A. Y. Lu,et al. Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[4] W. Pryor. Cytochrome P450: Structure, mechanism, and biochemistry , 1996 .
[5] A. P. Koley,et al. Differential Mechanisms of Cytochrome P450 Inhibition and Activation by α-Naphthoflavone* , 1997, The Journal of Biological Chemistry.
[6] P. Thomas,et al. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[7] A. Y. Lu,et al. Role of pharmacokinetics and metabolism in drug discovery and development. , 1997, Pharmacological reviews.
[8] F. Guengerich,et al. Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. , 1993, Archives of biochemistry and biophysics.
[9] C. W. Fisher,et al. Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[10] G. Granneman,et al. Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.
[11] K. Korzekwa,et al. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.
[12] H. Yamazaki,et al. Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. , 1996, Archives of biochemistry and biophysics.
[13] Metabolic interactions of putative cytochrome P4503A substrates with alternative pathways of dapsone metabolism in human liver microsomes. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[14] S. Wrighton,et al. The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.
[15] T. Shimada,et al. Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[16] K. Venkatesan. Pharmacokinetic Drug Interactions with Rifampicin , 1992, Clinical pharmacokinetics.
[17] A. D. Rodrigues,et al. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[18] F. Guengerich,et al. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. , 1997, Biochemistry.
[19] T. Rushmore,et al. INHIBITORY ANTI-CYP 3 A 4 PEPTIDE ANTIBODY : MAPPING OF INHIBITORY EPITOPE AND SPECIFICITY TOWARD OTHER CYP 3 A ISOFORMS , 1999 .
[20] I. H. Segel. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems , 1975 .
[21] T. Kronbach,et al. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. , 1989, Molecular pharmacology.
[22] F. Guengerich,et al. Human cytochrome P-450 enzymes. , 1992, Life sciences.
[23] F. Guengerich,et al. Expression of modified human cytochrome P450 2E1 in Escherichia coli, purification, and spectral and catalytic properties. , 1994, Archives of biochemistry and biophysics.
[24] C. W. Fisher,et al. The effects of cytochrome b5, NADPH-P450 reductase, and lipid on the rate of 6 beta-hydroxylation of testosterone as catalyzed by a human P450 3A4 fusion protein. , 1995, Archives of biochemistry and biophysics.
[25] B. Ring,et al. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. , 1998, Pharmacogenetics.
[26] A. Y. Lu,et al. Chapter 30. Inhibition of Cytochrome P-450 and Implications in Drug Development , 1997 .
[27] A. Y. Lu,et al. Inhibitory anti-CYP3A4 peptide antibody: mapping of inhibitory epitope and specificity toward other CYP3A isoforms. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[28] R. Weintraub,et al. Drug Interactions with Grapefruit Juice , 1997, Clinical pharmacokinetics.
[29] S. Imaoka,et al. Role of phospholipids in reconstituted cytochrome P450 3A form and mechanism of their activation of catalytic activity. , 1992, Biochemistry.
[30] F. Guengerich. Characterization of human cytochrome P450 enzymes , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[31] A. Rettie,et al. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.
[32] D. Waxman,et al. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. , 1986, The Journal of biological chemistry.
[33] M H Tarbit,et al. Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.
[34] A. P. Koley,et al. CO Binding Kinetics of Human Cytochrome P450 3A4 , 1995, Journal of Biological Chemistry.
[35] T. Kost,et al. CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4. , 1995, Archives of biochemistry and biophysics.
[36] T. Kamataki,et al. P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16 alpha-hydroxylase of dehydroepiandrosterone 3-sulfate. , 1987, The Journal of biological chemistry.
[37] T. Omura,et al. THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.
[38] A. P. Koley,et al. Drug-drug interactions: effect of quinidine on nifedipine binding to human cytochrome P450 3A4. , 1997, Biochemical pharmacology.
[39] H. Yamazaki,et al. Roles of Cytochrome b5in the Oxidation of Testosterone and Nifedipine by Recombinant Cytochrome P450 3A4 and by Human Liver Microsomes , 1996 .
[40] P. K. Smith,et al. Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.
[41] M. Franklin. Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes , 1977 .